Tonix Pharmaceuticals Holding Corp. (TNXP)
After hours:
| Previous close | 0.1800 |
| Open | 0.1840 |
| Bid | 0.1822 x 200 |
| Ask | 0.1844 x 800 |
| Day's range | 0.1820 - 0.1856 |
| 52-week range | 0.1200 - 2.1300 |
| Volume | |
| Avg. volume | 2,446,647 |
| Market cap | 17.446M |
| Beta (5Y monthly) | 2.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.8500 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.97 |
GlobeNewswireTonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET. A live webcast of the presentation can be found here. A replay of the p
- GlobeNewswire
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipel
- GlobeNewswire
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
CHATHAM, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present at the Planet MicroCap Showcase in Las Vegas, Nev. on May 1, 2024, at 8:00 a.m. PT (11:00 a.m. ET). The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonm
